Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab , in patients with microsatellite stable ... -Today at 07:31 am- MarketScreener
Melissa Forst Diwakar Davar Julissa Viana Roche Group Genentech United States Inc Research Development Rd Expenses
Source: marketscreener.com